IP Library Granted Patent US 12,690,608
Granted Patent B2
US 12,690,608 · App. 17/914,842 · Granted Jul 28, 2026

Arecoline salt and preparation method and product thereof

Inventors: Jin Lu (Shenzhen, CN); Guofeng Fu (Shenzhen, CN); Ming Chu (Shenzhen, CN); Xing Zhou (Shenzhen, CN); Wenwen Huang (Shenzhen, CN); Zhongli Xu (Shenzhen, CN); Yonghai Li (Shenzhen, CN)
Assignees: SHENZHEN FIRST UNION TECHNOLOGY CO., LTD.; SHENZHEN HERUI BIOTECHNOLOGY CO., LTD.
A24B15/167
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,690,608
App. No.
17/914,842
Filed
Sep 27, 2022
Granted
Jul 28, 2026
Kind
B2
Art Unit
1612
USPC
546/318
Abstract

This application provides an arecoline salt and a preparation method and a product thereof. The arecoline salt is a benzoate of arecoline, with a structural formula shown as follows: where X is a molar ratio of arecoline to benzoic acid. The arecoline salt, with good physicochemical stability, is convenient to use and widely used.

Claims (30)

1 . An arecoline salt, wherein the arecoline salt is benzoate of arecoline, with a structural formula as follows:

wherein X is a molar ratio of arecoline to benzoic acid and has a value of 0.5≤X≤10.

2 . The arecoline salt according to claim 1 , wherein X has a value of 0.5≤X≤2 0<X≤10 0<X≤8 0<X≤6 0<X≤5 0<X≤3 0<X≤2.

3 . The arecoline salt according to claim 2 , wherein the arecoline salt has a structural formula as follows:

4 . The arecoline salt according to claim 2 , wherein the arecoline salt has a structural formula as follows:

5 . The arecoline salt according to claim 2 , wherein the arecoline salt has a structural formula as follows:

6 . The arecoline salt according to claim 2 , wherein the arecoline salt has a structural formula as follows:

7 . A preparation method for an arecoline salt, comprising the following steps: placing arecoline in a reactor, adding benzoic acid under stirring and heating for dissolution to obtain the arecoline salt; wherein

the prepared arecoline salt has a structural formula as follows:

where X is a molar ratio of the arecoline to the benzoic acid and has a value of 0.5≤X≤10.

8 . The preparation method according to claim 7 , wherein the heating is carried out at 20-100° C., 20-80° C., further 40-80° C., further 50-80° C., or further 50-70° C.

9 . The preparation method according to claim 7 , wherein X has a value of 0.5≤X≤2 0<X≤10 0<X≤8 0<X≤6 0<X≤5.

10 . The preparation method according to claim 9 , wherein the prepared arecoline salt has a structural formula as one of the following:

11 . A preparation method for an arecoline salt, comprising the following steps:

dissolving arecoline hydrobromide in water to obtain an aqueous arecoline hydrobromide solution;

adjusting the aqueous arecoline hydrobromide solution to an alkalinity, and extracting with an organic solvent to obtain an organic solvent layer and a water layer; and

adding benzoic acid to the organic solvent layer for dissolution to obtain an arecoline salt;

wherein the arecoline salt has a structural formula as follows:

wherein X is a molar ratio of the arecoline to the benzoic acid and has a value of 0.5≤X≤10.

12 . The preparation method according to claim 11 , further comprising the following steps: adding water to the organic solvent layer for back extraction, and adjusting a water phase to an alkalinity to obtain a secondary organic solvent layer and a water layer; and

adding benzoic acid to the secondary organic solvent layer for dissolution to obtain an arecoline salt.

13 . The preparation method according to claim 12 , wherein the alkalinity is that the adjusted water phase has a pH value of 7-10, 7-9.5, further 7-9, further 7.5-9, or further 8-9.

14 . The preparation method according to claim 12 , wherein after the secondary organic solvent layer is dried, benzoic acid is added for dissolution to obtain an arecoline salt.

15 . The preparation method according to claim 11 , wherein the obtained arecoline salt is concentrated and dried to improve purity of the arecoline salt.

16 . The preparation method according to claim 11 , wherein the organic solvent is selected from the group consisting of at least one of:

ethyl acetate, benzene, toluene, xylene, petroleum ether, methyl ether, ethyl ether, methyl tert-butyl ether, dichloromethane, trichloromethane, ethyl acetate, tetrahydrofuran and n-butyl alcohol.

17 . A product with an areca nut flavor, wherein the product comprises the arecoline salt according to claim 1 .

18 . The product according to claim 17 , wherein the product is an aerosol generation substrate configured to be atomized to generate a smokable aerosol; or the product is a filter capsule, a chewing gum, or a beverage.

19 . The product according to claim 17 , wherein the aerosol generation substrate is a liquid phase configured to be atomized by any one of a heating atomizer, an ultrasonic atomizer, an air compression atomizer, or a press-type spraying device to generate an aerosol.

20 . The product according to claim 17 , wherein the aerosol generation substrate is a solid phase configured to generate a smokable aerosol when heated below an ignition point.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2023
From: SHENZHEN ICYBETEL BIOLOGICAL TECHNOLOGY CO., LTD.
To: SHENZHEN FIRST UNION TECHNOLOGY CO., LTD.; SHENZHEN HERUI BIOTECHNOLOGY CO., LTD.
Reel/Frame 065948/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2022
From: LU, JIN; FU, GUOFENG; CHU, MING; ZHOU, XING; HUANG, WENWEN; XU, ZHONGLI; LI, YONGHAI
To: SHENZHEN ICYBETEL BIOLOGICAL TECHNOLOGY CO., LTD.
Reel/Frame 061223/0472 →
Priority Claims (2)
CN 202010227895.8 · Mar 27, 2020 · national
CN 202010588490.7 · Jun 24, 2020 · national
Continuity (1)
Related Publication 20230148653A1 · May 18, 2023
References Cited (19)
US 2557353A · Kartsonis et al. · 1951 [cited by applicant]
US 20110139166A1 · Luzenberg, Jr. · 2011 [cited by applicant]
CN 1186614A · 1998 [cited by applicant]
CN 1651432 · 2005 [cited by examiner]
CN 1651432A · 2005 [cited by examiner]
CN 101624368 · 2010 [cited by examiner]
CN 101624368A · 2010 [cited by examiner]
CN 101912496A · 2010 [cited by applicant]
CN 103461641A · 2013 [cited by applicant]
CN 103504431A · 2014 [cited by applicant]
CN 105263345A · 2016 [cited by applicant]
CN 109288115A · 2019 [cited by applicant]
CN 110771946A · 2020 [cited by applicant]
JP S5094132 · 1975 [cited by applicant]
JP H11192069A · 1999 [cited by applicant]
WO 2018207888A1 · 2018 [cited by applicant]
Johnson et al (International Journal of Toxicology, 2017, vol. 36 (Supplement 3) 5S-30S). (Year: 2017). [cited by examiner]
Japanese Notice of Reasons for Refusal dated Dec. 25, 2025 received in Japanese Patent Application No. 2024-174421. [cited by applicant]
Notification of Examination Opinion dated Nov. 28, 2025 received in Taiwanese Patent Application No. 110123206. [cited by applicant]